Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Apellis Pharmaceuticals Inc. (APLS) Insider Trading Activity
Healthcare • Biotechnology • 702 employees
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Total Value
-$2,770,130.35
Total Shares
344,592
Average Trade Value
-$43,970.32
Most Active Insider
Francois Cedric
Total Activity: $864,932
Largest Single Transaction
$412,296
by Francois Cedric on Jan 22, 2025
30-Day Activity
1 Transaction
Volume: 16,483 shares
Value: $10,000
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Director
|
Apr 17, 2025 | 16,483 | $10,000 | 16,483 (+100.0%) | Grant | |
|
Vp/chief Accounting Officer
Officer
|
Mar 17, 2025 | 183 | $4,543 | 47,955 (-0.4%) | Sale | |
|
General Counsel
|
Mar 5, 2025 | 5,569 | $139,789 | 138,730 (-4.0%) | Sale | |
|
Chief Business Strat Officer
Officer
|
Feb 11, 2025 | 363 | $10,360 | 83,945 (-0.4%) | Sale | |
|
Chief Business Strat Officer
Officer
|
Jan 29, 2025 | 365 | $10,776 | 84,308 (-0.4%) | Sale | |
|
Chief Commercial Officer
Officer
|
Jan 29, 2025 | 695 | $20,519 | 84,050 (-0.8%) | Sale | |
|
General Counsel
Officer
|
Jan 29, 2025 | 695 | $20,519 | 144,299 (-0.5%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Jan 29, 2025 | 2,824 | $83,375 | 415,695 (-0.7%) | Sale | |
|
Chief Scientific Officer
Officer
|
Jan 29, 2025 | 826 | $24,386 | 1,147,716 (-0.1%) | Sale | |
|
Chief Financial Officer
Officer
|
Jan 29, 2025 | 546 | $16,120 | 128,665 (-0.4%) | Sale | |
|
Chief People Officer
Officer
|
Jan 29, 2025 | 364 | $10,747 | 70,251 (-0.5%) | Sale | |
|
Chief Development Officer
Officer
|
Jan 29, 2025 | 278 | $8,208 | 55,312 (-0.5%) | Sale | |
|
Chief Technical Officer
Officer
|
Jan 29, 2025 | 825 | $24,357 | 83,664 (-1.0%) | Sale | |
|
Chief Commercial Officer
Officer
|
Jan 22, 2025 | 3,323 | $101,104 | 84,745 (-3.9%) | Sale | |
|
Chief Development Officer
Officer
|
Jan 22, 2025 | 1,291 | $39,279 | 55,590 (-2.3%) | Sale | |
|
General Counsel
Officer
|
Jan 22, 2025 | 3,323 | $101,104 | 144,994 (-2.3%) | Sale | |
|
Chief Business Strat Officer
Officer
|
Jan 22, 2025 | 1,396 | $42,474 | 84,673 (-1.6%) | Sale | |
|
Vp/chief Accounting Officer
Officer
|
Jan 22, 2025 | 1,096 | $33,346 | 48,138 (-2.3%) | Sale | |
|
Chief People Officer
Officer
|
Jan 22, 2025 | 1,751 | $53,275 | 70,615 (-2.5%) | Sale | |
|
Chief Financial Officer
Officer
|
Jan 22, 2025 | 3,088 | $93,954 | 129,211 (-2.4%) | Sale | |
|
Chief Technical Officer
Officer
|
Jan 22, 2025 | 3,948 | $120,120 | 84,489 (-4.7%) | Sale | |
|
Chief Scientific Officer
Officer
|
Jan 22, 2025 | 3,948 | $120,120 | 1,148,542 (-0.3%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Jan 22, 2025 | 13,551 | $412,296 | 418,519 (-3.2%) | Sale | |
|
Chief People Officer
Officer
|
Jan 21, 2025 | 28,508 | $10,000 | 72,366 (+39.4%) | Grant | |
|
Chief Scientific Officer
Officer
|
Jan 21, 2025 | 15,045 | $10,000 | 1,152,490 (+1.3%) | Grant | |
|
General Counsel
Officer
|
Jan 21, 2025 | 42,762 | $10,000 | 148,317 (+28.8%) | Grant | |
|
Chief Technical Officer
Officer
|
Jan 21, 2025 | 36,426 | $10,000 | 88,437 (+41.2%) | Grant | |
|
Chief Financial Officer
Officer
|
Jan 21, 2025 | 45,929 | $10,000 | 132,299 (+34.7%) | Grant | |
|
Chief Executive Officer
Director, Officer
|
Jan 21, 2025 | 130,662 | $10,000 | 432,070 (+30.2%) | Grant | |
|
Vp/chief Accounting Officer
Officer
|
Jan 21, 2025 | 12,591 | $10,000 | 49,234 (+25.6%) | Grant | |
|
Chief Medical Officer
Officer
|
Jan 21, 2025 | 39,594 | $10,000 | 93,301 (+42.4%) | Grant | |
|
Chief Business Strat Officer
Officer
|
Jan 21, 2025 | 28,508 | $10,000 | 86,069 (+33.1%) | Grant | |
|
Chief Scientific Officer
Officer
|
Jan 17, 2025 | 750 | $22,469 | 1,137,445 (-0.1%) | Sale | |
|
Chief Business Strat Officer
Officer
|
Jan 17, 2025 | 1,235 | $36,998 | 57,561 (-2.1%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Jan 17, 2025 | 6,007 | $179,959 | 301,408 (-2.0%) | Sale | |
|
Chief People Officer
Officer
|
Jan 17, 2025 | 1,241 | $37,178 | 43,858 (-2.8%) | Sale | |
|
General Counsel
Officer
|
Jan 17, 2025 | 2,201 | $65,938 | 105,555 (-2.1%) | Sale | |
|
Chief Financial Officer
Officer
|
Jan 17, 2025 | 1,730 | $51,828 | 86,370 (-2.0%) | Sale | |
|
Chief Medical Officer
Officer
|
Jan 17, 2025 | 1,853 | $55,513 | 53,707 (-3.5%) | Sale | |
|
Vp/chief Accounting Officer
Officer
|
Jan 17, 2025 | 715 | $21,420 | 36,643 (-2.0%) | Sale | |
|
Chief Commercial Officer
Officer
|
Jan 17, 2025 | 2,201 | $65,938 | 88,068 (-2.5%) | Sale | |
|
Chief Technical Officer
Officer
|
Jan 17, 2025 | 2,145 | $64,260 | 52,011 (-4.1%) | Sale | |
|
Chief Technical Officer
Officer
|
Jan 13, 2025 | 2,632 | $75,544 | 54,156 (-4.9%) | Sale | |
|
Chief People Officer
Officer
|
Jan 13, 2025 | 1,599 | $45,895 | 45,099 (-3.5%) | Sale | |
|
Chief Financial Officer
Officer
|
Jan 13, 2025 | 2,170 | $62,284 | 88,100 (-2.5%) | Sale | |
|
General Counsel
Officer
|
Jan 13, 2025 | 4,965 | $142,506 | 107,756 (-4.6%) | Sale | |
|
Vp/chief Accounting Officer
Officer
|
Jan 13, 2025 | 783 | $22,474 | 37,358 (-2.1%) | Sale | |
|
Chief Development Officer
Officer
|
Jan 13, 2025 | 264 | $7,577 | 56,881 (-0.5%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Jan 13, 2025 | 6,247 | $179,302 | 307,415 (-2.0%) | Sale | |
|
Chief Scientific Officer
Officer
|
Jan 13, 2025 | 2,288 | $65,670 | 1,138,195 (-0.2%) | Sale | |
|
Chief Business Strat Officer
Officer
|
Jan 13, 2025 | 1,599 | $45,895 | 58,796 (-2.7%) | Sale | |
|
Chief Commercial Officer
Officer
|
Jan 13, 2025 | 2,685 | $77,065 | 90,269 (-3.0%) | Sale | |
|
Director
|
Jan 8, 2025 | 9,090 | $10,000 | 9,090 (+100.0%) | Grant | |
|
Chief Medical Officer
Officer
|
Jan 6, 2025 | 2,816 | $95,215 | 55,560 (-5.1%) | Sale | |
|
Director
|
Jan 1, 2025 | 6,267 | $10,000 | 17,705 (+35.4%) | Grant | |
|
Director
|
Jan 1, 2025 | 6,267 | $10,000 | 22,705 (+27.6%) | Grant | |
|
Director
|
Jan 1, 2025 | 6,267 | $10,000 | 377,028 (+1.7%) | Grant | |
|
Director
|
Jan 1, 2025 | 6,267 | $10,000 | 158,393 (+4.0%) | Grant | |
|
Director
|
Jan 1, 2025 | 6,267 | $10,000 | 17,705 (+35.4%) | Grant | |
|
Chief Financial Officer
Officer
|
Dec 31, 2024 | 10,054 | $139,248 | 90,270 (+11.1%) | Exercise/Conversion | |
|
Chief Financial Officer
Officer
|
Dec 31, 2024 | 1,042 | $15,578 | 80,216 (+1.3%) | Exercise/Conversion | |
|
Chief Development Officer
Officer
|
Dec 23, 2024 | 63 | $2,085 | 57,145 (-0.1%) | Sale | |
|
General Counsel
|
Dec 11, 2024 | 5,000 | $171,175 | 112,721 (-4.4%) | Sale |